Multidrug resistance in B-cell chronic lymphocytic leukemia

Acta Haematol. 1995;94(2):78-83. doi: 10.1159/000203978.

Abstract

Multidrug resistance (MDR) was investigated in peripheral blood cells isolated from 40 patients with B cell chronic lymphocytic leukemia (B-CLL) and from 7 healthy volunteers, using a flow cytometric assay that detects cellular efflux of the fluorescent dye rhodamine 123 (Rh 123), which has been demonstrated to be transported from the cell by the P-glycoprotein pump. The proportion of B leukemic cells effluxing Rh 123 and thus displaying MDR was low (14 +/- 17%) in B-CLL and in only 4 cases did the contingent of B leukemic cells showing MDR represent more than 30% of the total leukemic cells. In contrast, a higher proportion of cells effluxing Rh 123 (44 +/- 13%) was demonstrated in normal B lymphocytes. No statistical correlation was found between the number of leukemic B cells displaying MDR and clinical parameters or previous treatment. These results clearly suggest that MDR activity is usually low in B-CLL.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / blood*
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
  • Adult
  • Aged
  • Aged, 80 and over
  • Drug Resistance, Multiple* / genetics
  • Drug Resistance, Neoplasm* / genetics
  • Flow Cytometry
  • Fluorescent Antibody Technique
  • Gene Expression
  • Humans
  • Immunophenotyping
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukocytes, Mononuclear / chemistry
  • Leukocytes, Mononuclear / pathology
  • Middle Aged
  • Polymerase Chain Reaction
  • Rhodamines

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Rhodamines